PlumX Metrics
Embed PlumX Metrics

The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

Clinical Immunology, ISSN: 1521-6616, Vol: 215, Page: 108450
2020
  • 238
    Citations
  • 0
    Usage
  • 288
    Captures
  • 0
    Mentions
  • 22
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    238
  • Captures
    288
  • Social Media
    22
    • Shares, Likes & Comments
      22
      • Facebook
        22

Article Description

Acute respiratory distress syndrome (ARDS) is a devastating clinical manifestation of COVID-19 pneumonia and is mainly based on an immune-driven pathology. Mounting evidence suggests that COVID-19 is fueled by a maladaptive host inflammatory response that involves excessive activation of innate immune pathways. While a “cytokine storm” involving IL-6 and other cytokines has been documented, complement C3 activation has been implicated as an initial effector mechanism that exacerbates lung injury in preclinical models of SARS-CoV infection. C3-targeted intervention may provide broader therapeutic control of complement-mediated inflammatory damage in COVID-19 patients. Herein, we report the clinical course of a patient with severe ARDS due to COVID-19 pneumonia who was safely and successfully treated with the compstatin-based complement C3 inhibitor AMY-101.

Bibliographic Details

Mastaglio, Sara; Ruggeri, Annalisa; Risitano, Antonio M; Angelillo, Piera; Yancopoulou, Despina; Mastellos, Dimitrios C; Huber-Lang, Markus; Piemontese, Simona; Assanelli, Andrea; Garlanda, Cecilia; Lambris, John D; Ciceri, Fabio

Elsevier BV

Medicine; Immunology and Microbiology

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know